Key clinical point: Locoregional therapy does not offer a survival benefit in patients with metastatic breast cancer treated with optimal systemic therapy.
Major finding: The median overall survival was 54 months, both for patients who received continued systemic therapy and for those who received early local therapy.
Study details: A phase 3 trial of 256 patients with stage IV breast cancer and an intact primary tumor.
Disclosures: The trial was supported by the National Cancer Institute and Canadian Cancer Society. Dr. Khan reported no conflicts of interest.
Khan SA et al. ASCO 2020, Abstract LBA2.